Unlisted Markets

Intas Pharmaceuticals Limited

Healthcare · Pharma (Generics & Biosimilars)

Unlisted / private marketUnlistedScreened Candidate
Prospera Indicative PriceIndicative price unavailable

Awaiting a verified source quote. No third-party quote is on record for this company yet, so there is no indicative price to show — and we would rather leave it blank than print a number we cannot stand behind. Our team can confirm the current dealable level directly.

Indicative private-market reference — not an exchange quote. Not investment advice.

Implied valuation
Not available
Revenue growth
Not disclosed
EBITDA margin
Not disclosed
Prospera Score
Not yet scored
Orientation

What the market says, and what we know.

Two separate things, deliberately shown side by side: a sourced private-market price reference, and the depth of research that actually stands behind this company today.

Market reference

No third-party quote has been sourced for this company yet, so there is no market reference to show. Ask us to check the current level and we will come back with what the market is actually doing.

Prospera researchScreened Candidate
  1. Research Universe — availableCatalogued as a strategically relevant private-market company.
  2. Basic Research — availableBusiness and ownership facts verified against primary sources — 2 sourced records on file.
  3. Deep Research — not availableNot started. No financials, no implied valuation and no Prospera Score exist for this company.
  4. Prospera Recommendation — not availableNo Prospera view has been published. Presence in the universe is not a recommendation.
Price history

Indicative Private-Market Price History

Real, dated third-party observations only — plotted where they exist, never interpolated, extended or carried forward. This is a record of private-market sightings, not a live exchange chart.

Price history not available. No dated third-party quotes have been sourced for this company yet.

What the company does

The business, in plain English.

Assembled only from records that exist for this company. Anything not disclosed says so.

Founded
1977
Headquarters
Ahmedabad, Gujarat
Sector
Healthcare · Pharma (Generics & Biosimilars)
Promoters
Binish Chudgar

What it does

Intas Pharmaceuticals is India's largest privately held pharmaceutical company by revenue, developing and manufacturing generic and specialty formulations and biosimilars across cardiology, oncology, diabetes and other therapy areas, with roughly 60% of revenue from international markets via its subsidiary Accord Healthcare. It was established in Ahmedabad in 1977 by Hasmukh Chudgar, and the Chudgar family (led by Vice-Chairman and MD Binish Chudgar) continues to hold roughly 84% of the company. FY26 revenue was reported at around Rs. 24,000 crore.

Source: Wikipedia

Why it matters

Competes with listed Indian generics majors Sun Pharma, Cipla, Lupin, Dr. Reddy's and Torrent Pharmaceuticals, both domestically and in export markets.

Source: Not attributed

Ownership structure

Chudgar family holds approximately 84%; Temasek/Abu Dhabi Investment Authority and ChrysCapital hold minority institutional stakes

Promoters & principal holders: Binish Chudgar

Private-market context

Unlisted, family-controlled with institutional minority investors

UnlistedPre-IPODRHP FiledPublic

What to understand before investing

  • Unlisted shares can be difficult to sell. There may be no continuous market and no guaranteed buyer at the price you see.
  • Any price shown here is an indicative private-market reference, not an exchange quote and not an executable price.
  • An expected IPO may be delayed, repriced or never happen at all.
  • A good company can still be a poor investment at the wrong valuation.
These are standing characteristics of the asset class, not findings about this company. Company-specific risks appear below only where they have been researched.
Research status

Research is not yet complete for this company.

We would rather say that plainly than publish a page that looks finished.

No financials, no implied valuation and no peer comparison have been researched for this company yet.

No Prospera Private Market Score and no Prospera view exist. Being in our universe is not a recommendation, and we will not manufacture one to fill this space.

What you can rely on above is what has actually been verified: the company's identity and business facts, any sourced price observations on record, and any risks that have been documented. If you want us to prioritise deeper work here, ask — that is genuinely how the queue gets set.

Risk

What could go wrong.

Documented, per-company risks — grouped by the categories the research itself recorded. There is no risk score here, because we do not compute one.

No company-specific risks have been researched and recorded for this company yet. That is an absence of research, not a clean bill of health — the standing risks of the asset class above still apply.

Corporate events

What's happened, and why it matters.

Dated, sourced events only — recorded as they were reported, in reverse order of significance to a private-market holder.

No corporate events have been documented for this company yet.

Sources & evidence

Everything traceable.

Every figure on this page comes from one of the records below. Where a source published a link, it is here.

FieldSourceAs of
Business DescriptionWikipediaNot disclosed
Competitive PositionNot attributedNot disclosed
Next step

Interested in Intas Pharmaceuticals Limited?

Every option below opens a conversation with a person at Prospera. Nothing here places, reserves or executes an order.

We will come back with the current dealable level, the available lot size and what the process actually involves. Indicative prices shown on this page are private-market references, not executable quotes.